Compare CCEL & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCEL | NEPH |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 39.0M |
| IPO Year | 2022 | 2004 |
| Metric | CCEL | NEPH |
|---|---|---|
| Price | $4.42 | $3.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 10.5K | ★ 35.2K |
| Earning Date | 10-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | ★ 0.23 | 0.12 |
| Revenue | ★ $25,384,279.00 | $18,789,000.00 |
| Revenue This Year | N/A | $17.81 |
| Revenue Next Year | N/A | $15.90 |
| P/E Ratio | ★ $15.87 | $29.25 |
| Revenue Growth | 9.76 | ★ 32.67 |
| 52 Week Low | $2.72 | $2.66 |
| 52 Week High | $4.90 | $6.42 |
| Indicator | CCEL | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 42.92 |
| Support Level | $3.15 | $2.86 |
| Resistance Level | $4.71 | $3.78 |
| Average True Range (ATR) | 0.38 | 0.30 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 53.06 | 43.65 |
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.